Skip to main content

Peer Review reports

From: Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

Original Submission
14 Aug 2004 Submitted Original manuscript
20 Sep 2004 Reviewed Reviewer Report - Craig Ritchie
4 Oct 2004 Reviewed Reviewer Report - Krista L. Lanctot
8 Nov 2004 Author responded Author comments - Mary LuAnne Lilly
Resubmission - Version 2
8 Nov 2004 Submitted Manuscript version 2
29 Nov 2004 Reviewed Reviewer Report - Craig Ritchie
2 Dec 2004 Reviewed Reviewer Report - Krista L. Lanctot
13 Jan 2005 Author responded Author comments - Mary LuAnne Lilly
Resubmission - Version 3
13 Jan 2005 Submitted Manuscript version 3
Publishing
19 Jan 2005 Editorially accepted
19 Jan 2005 Article published 10.1186/1471-2318-5-3

You can find further information about peer review here.

Back to article page